We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

302 hedge funds and large institutions have $4.58B invested in Bio-Rad Laboratories Class A in 2017 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 101 increasing their positions, 102 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 24

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

11% more funds holding

Funds holding: 271302 (+31)

7% more capital invested

Capital invested by funds: $4.27B → $4.58B (+$318M)

0.34% less ownership

Funds ownership: 78.25%77.91% (-0.34%)

1% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 102

74% less call options, than puts

Call options by funds: $2.1M | Put options by funds: $8.14M

Holders
302
Holders Change
+31
Holders Change %
+11.44%
% of All Funds
6.85%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
57
Increased
101
Reduced
102
Closed
24
Calls
$2.1M
Puts
$8.14M
Net Calls
-$6.04M
Net Calls Change
-$7.55M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$44.2M -$7.12M -29,398 -14%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$44M -$5.49M -22,644 -11%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$43M +$1.41M +5,819 +3%
Millennium Management
29
Millennium Management
New York
$43M +$23.1M +95,235 +112%
Norges Bank
30
Norges Bank
Norway
$41.6M
PAMP
31
Polar Asset Management Partners
Ontario, Canada
$39.3M +$16.4M +67,595 +70%
Westfield Capital Management
32
Westfield Capital Management
Massachusetts
$35.6M +$11.9M +49,255 +49%
Fidelity Investments
33
Fidelity Investments
Massachusetts
$34.4M -$3.46M -14,258 -9%
Goldman Sachs
34
Goldman Sachs
New York
$34.2M +$9.99M +41,208 +40%
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$33.1M +$277K +1,145 +0.8%
TM
36
Tikvah Management
North Carolina
$32.9M
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$32.5M +$30.2M +124,666 +1,081%
Neuberger Berman Group
38
Neuberger Berman Group
New York
$31.3M -$29.1K -120 -0.1%
Charles Schwab
39
Charles Schwab
California
$29.3M +$1.05M +4,332 +4%
CCM
40
Clearfield Capital Management
New York
$28.6M -$18.3M -75,613 -39%
BCM
41
BlueCrest Capital Management
Jersey
$26.9M +$9.78M +40,347 +56%
EARNEST Partners
42
EARNEST Partners
Georgia
$26.1M -$1.32M -5,464 -5%
CRM
43
Cramer Rosenthal McGlynn
Connecticut
$25.4M -$41.4M -170,874 -62%
Russell Investments Group
44
Russell Investments Group
United Kingdom
$23.9M +$808K +3,335 +3%
PPA
45
Parametric Portfolio Associates
Washington
$23M +$200K +827 +0.9%
SGA
46
Sector Gamma AS
Norway
$22.7M -$3.49M -14,400 -13%
HP
47
Hosking Partners
United Kingdom
$22.5M +$1.6M +6,586 +7%
Adage Capital Partners
48
Adage Capital Partners
Massachusetts
$22.3M -$1.58M -6,500 -7%
Deutsche Bank
49
Deutsche Bank
Germany
$22M +$15.5M +64,016 +229%
SEI Investments
50
SEI Investments
Pennsylvania
$21.9M +$4.34M +17,890 +24%

BIO Hedge Fund Activity: Q4 2017 in Review

302 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2017, worth a combined $4.58B — up 7.5% from $4.27B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new BIO positions and 24 closed out — a net gain of 33 holders — while 101 added to existing stakes and 102 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $52M. The largest seller was Ariel Investments, cutting an estimated $62.2M.

  • 302 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2017, up from 271 in Q3 2017.
  • Funds reported $4.58B of Bio-Rad Laboratories Class A stock for Q4 2017, up 7.5% quarter-over-quarter.
  • 57 funds opened new Bio-Rad Laboratories Class A positions in Q4 2017 and 24 closed out, a net change of +33 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q4 2017 was Renaissance Technologies, an estimated $52M added.
  • The largest Bio-Rad Laboratories Class A seller in Q4 2017 was Ariel Investments, an estimated $62.2M sold.

Based on aggregated 13F filings for Q4 2017.